New Once-Daily Version of Tramadol Approved for Chronic Pain
The US Food and Drug Administration has approved Labopharms once-daily extended-release formulation of the analgesic tramadol (Ryzolt) for the management of moderate to moderately severe chronic pain in adults who require around-the-clock long-term treatment of pain.
The US Food and Drug Administration has approved Labopharms once-daily extended-release formulation of the analgesic tramadol (Ryzolt) for the management of moderate to moderately severe chronic pain in adults who require around-the-clock long-term treatment of pain.
Ryzolt is a centrally acting analgesic with both immediate-release and extended-release characteristics. Labopharms US marketing partner, Purdue Pharma, anticipates launching the drug in 100-mg, 200-mg, and 300-mg tablets in the second quarter of 2009.
![We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fd5a069c33bbfe917bc7c0b1bb13d76c0a815cc44-234x234.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.")
